ACCORD is sponsored by the National Institutes of Health (National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive Diseases, and the Eye Institute) and the Centers for Disease Control. ACCORD is comprised of 7 regional networks. Seven network hubs coordinate more than 70 clinical centers in the United States and Canada. ACCORD plans to recruit 10,000 patients and follow them up to eight years. In January 2005, ACCORD had more than 7,500 particiants.
The Northeastern Network
Hub is on the Columbia University Health Sciences campus and its 13 clinical centers are located in New York and New Jersey.
On 1/10/01, ACCORD launched a pilot study, called vanguard phase. On 1/11/01, the Northeastern Network recruited the first two patients in the entire ACCORD program. After 5 months of recruiting activity, 1184 patients had been recruited in the United States and Canada, 170 of them in the Northeastern Network, which represents 142% of the Northeastern Network's goal.
The Northeastern Network was the first ACCORD network to reach its recruitment goal in the vanguard phase.
The vanguard phase results prompted some protocol improvements. In January 2003, the ACCORD main trial started a 30-month recruiting period. More than 6,000 participants have been recruited for the main trial. Follow-up will continue until 2009.
WHAT IS ACCORD?
(ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES)
Click here to Email ACCORD
ACCORD is an international research program to develop treatment strategies to reduce cardiovascular complications of type 2 diabetes mellitus. ACCORD will evaluate medical treatment strategies to control blood sugar, blood pressure, and blood cholesterol. Hopefully, these strategies will substantially prevent or delay cardiovascular events that threaten patients with diabetes mellitus: heart attack, stroke, and other vascular diseases.